natgillin/translations-raw huggingface dataset:
Each orodispersible tablet contains 142.5 mg lactose, 0.7875 mg sucrose and 6.75 mg aspartame (E951).
Ena orodisperzibilna tableta vsebuje 142,5 mg laktoze, 0,7875 mg saharoze in 6,75 mg aspartama (E951).
13 Following short term treatment (median duration 22 days), weight gain ≥7% of baseline body weight (kg) was very common (40.6%), ≥15% of baseline body weight was common (7.1%) and
13 S kratkotrajnim zdravljenjem (srednje trajanje 22 dni) povezano povečanje telesne mase za ≥ 7 % od osnovne telesne mase (kg) je bilo zelo pogosto (40,6 %), ≥ 15 % pogosto (7,1 %) in za ≥ 25 %
Common side effects (may affect up to 1 in 10 people) include changes in the levels of some blood cells, circulating fats and early in treatment, temporary increases in liver enzymes; increases in the level of sugars in the blood and urine; increases in levels of uric acid and creatine phosphokinase in the blood; feeling more hungry; dizziness; restlessness; tremor; unusual movements (dyskinesias); constipation; dry mouth; rash; loss of strength; extreme tiredness; water retention leading to swelling of the hands, ankles or feet; fever; joint pain; and sexual dysfunctions such as decreased libido in males and females or erectile dysfunction in males
Pogosti neželeni učinki (lahko prizadenejo do 1 od 10 bolnikov) vključujejo spremembe v ravneh nekaterih krvnih celic, maščob v krvnem obtoku in v začetnih obdobjih zdravljenja, začasno povišanje jetrnih encimov, zvišanja v ravni sladkorjev v krvi in urinu, zvišanja v ravni sečne kisline in kreatinfosfokinaze v krvi, večji občutek lakote, omotico, nemirnost, tresenje, nenavadne gibe (diskinezijo), zaprtje, suha usta, izpuščaj, izgubo moči, hudo utrujenost, zadrževanje vode, ki vodi v otekanje rok, gležnjev ali nog, vročino, bolečine v sklepih ter spolne disfunkcije, kot na primer zmanjšan libido pri moških in ženskah ter erektilna disfunkcija pri moških.
Signs and symptoms
Symptoms).
4 Observed for fasting normal levels at baseline (<5.56 mmol/l) which increased to high (≥7 mmol/l).
4 Opazovano pri osnovnih normalnih ravneh na tešče (< 5,56 mmol/l), ki so se povišale na visoke (≥ 7 mmol/l).
3 Observed for fasting normal levels at baseline (<5.17 mmol/l) which increased to high (≥6.2 mmol/l).
3 Opazovano pri osnovnih normalnih ravneh na tešče (< 5,17 mmol/l), ki so se povišale na visoke (≥ 6,2 mmol/l).
Each orodispersible tablet contains 190.0 mg lactose, 1.05 mg sucrose and 9.0 mg aspartame (E951).
Ena orodisperzibilna tableta vsebuje 190,0 mg laktoze, 1,05 mg saharoze in 9,0 mg aspartama (E951).
- The other ingredients are mannitol, aspartame (E951), magnesium stearate, crospovidone type B, lactose monohydrate, hydroxypropylcellulose and lemon flavour [flavouring preparation(s), maltodextrin, sucrose, gum arabic (E414), glyceryl triacetate (E1518) and alphatocopherol (E307)].
- Druge sestavine so:manitol, aspartam (E951), magnezijev stearat, krospovidon tipa B, laktoza monohidrat, hidroksipropilceluloza in limonina aroma [pripravek/ki arome, maltodekstrin,
Olanzapine is not recommended for use in children and adolescents below 18 years of age due to a lack of data on safety and efficacy.
Pediatrična populacija Zaradi pomanjkanja podatkov glede varnosti in učinkovitosti, olanzapina ne priporočamo za uporabo pri otrocih in mladostnikih mlajših od 18 let.
Olanzapine Teva orodispersible tablets are for oral use.
Olanzapin Teva obložene tablete so za peroralno uporabo.
The most frequently (seen in ≥1% of patients ) reported adverse reactions associated with the use of olanzapine in clinical trials were somnolence, weight gain, eosinophilia, elevated prolactin, cholesterol, glucose and triglyceride levels (see section 4.4), glucosuria, increased appetite, dizziness, akathisia, parkinsonism, leukopenia, neutropenia (see section 4.4), dyskinesia, orthostatic hypotension, anticholinergic effects, transient asymptomatic elevations of hepatic aminotransferases (see section 4.4), rash, asthenia, fatigue, pyrexia, arthralgia, increased alkaline phosphatase, high gamma glutamyltransferase, high uric acid, high creatine phosphokinase and oedema.
Najpogosteje poročani (opažene pri ≥ 1 % bolnikov) neželeni učinki, povezani z uporabo olanzapina v kliničnih preskušanjih, so bili zaspanost, povečanje telesne mase, eozinofilija, zvišane ravni prolaktina, holesterola, glukoze in trigliceridov (glejte poglavje 4.4), glikozurija, povečan apetit, omotica, akatizija, parkinsonizem, levkopenija, nevtropenija (glejte poglavje 4.4), diskinezija,
Excipient with known effect Each film-coated tablet contains 68.9 mg lactose.
Ena filmsko obložena tableta vsebuje 68,9 mg laktoze.
Olanzapine Teva 5 mg orodispersible tablets Olanzapine Teva 10 mg orodispersible tablets Olanzapine Teva 15 mg orodispersible tablets Olanzapine Teva 20 mg orodispersible tablets
Olanzapin Teva 5 mg orodisperzibilne tablete Olanzapin Teva 10 mg orodisperzibilne tablete Olanzapin Teva 15 mg orodisperzibilne tablete Olanzapin Teva 20 mg orodisperzibilne tablete
5 Observed for fasting normal levels at baseline (<1.69 mmol/l) which increased to high
Opazovano pri osnovnih normalnih ravneh na tešče (< 1,69 mmol/l), ki so se povišale na visoke
Hepatobiliary disorders Transient, asymptomatic elevations of hepatic
Prehodna asimptomatska zvišanja jetrnih aminotransferaz (ALT,
Other medically significant sequelae of overdose include delirium, convulsion, coma, possible neuroleptic malignant syndrome, respiratory depression, aspiration, hypertension or hypotension,
Druge zdravstveno pomembne posledice prevelikega odmerjanja vključujejo delirij, konvulzije, komo, možen nevroleptični maligni sindrom, depresijo dihanja, aspiracijo, hipertenzijo ali hipotenzijo, motnje srčnega ritma (< 2 % primerov prevelikega odmerjanja) in kardiopulmonalni zastoj.
In particular, tell your doctor if you are taking: - medicines for Parkinson's disease.
Še zlasti pa povejte svojemu zdravniku, če jemljete:
Tell your doctor immediately if you have: - unusual movement (a common side effect that may affect up to 1 in 10 people) mainly of the face or tongue; - blood clots in the veins (an uncommon side effect that may affect up to 1 in 100 people) especially in the legs (symptoms include swelling, pain, and redness in the leg), which may travel through blood vessels to the lungs causing chest pain and difficulty in breathing.
- krvne strdke v venah (občasen neželeni učinek, ki lahko prizadene do 1 od 100 bolnikov), posebej v nogah (simptomi vključujejo otekanje, bolečino in rdečino na nogah), ki lahko po žilah potujejo v pljuča ter povzročijo bolečino v pljučih in težave z dihanjem.
Excipient with known effect Each film-coated tablet contains 206.7 mg lactose.
Ena filmsko obložena tableta vsebuje 206,7 mg laktoze.
3 Observed for fasting normal levels at baseline (<5.17 mmol/l) which increased to high
3 Opazovano pri osnovnih normalnih ravneh na tešče (< 5,17 mmol/l), ki so se povišale na visoke
Each orodispersible tablet contains 47.5 mg lactose, 0.2625 mg sucrose and 2.25 mg aspartame (E951).
Ena orodisperzibilna tableta vsebuje 47,5 mg laktoze, 0,2625 mg saharoze in 2,25 mg aspartama (E951).
Olanzapine Teva 5 mg, 10 mg and 15 mg orodispersible tablets are available in cartons containing 28, 30, 35, 50, 56, 70 or 98 tablets.
Olanzapin Teva 5 mg, 10 mg in 15 mg orodisperzibilne tablete so na voljo v pakiranjih po 28, 30, 35, 50, 56, 70 ali 98 orodisperzibilnih tablet.
Uncommon side effects (may affect up to 1 in 100 people) include hypersensitivity (e.g. swelling in the mouth and throat, itching, rash); diabetes or the worsening of diabetes, occasionally associated with ketoacidosis (ketones in the blood and urine) or coma; seizures, usually associated with a history of seizures (epilepsy); muscle stiffness or spasms (including eye movements); restless legs syndrome; problems with speech; stuttering; slow heart rate; sensitivity to sunlight; bleeding from the nose; abdominal distension; memory loss or forgetfulness; urinary incontinence; lack of ability to urinate; hair loss; absence or decrease in menstrual periods; and changes in breasts in males and females such as an abnormal production of breast milk or abnormal growth.
občasno povezano s ketoacidozo (ketoni v krvi in urinu) ali komo, krče, običajno povezane s krči (epileptičnimi napadi) v preteklosti, mišično okorelost ali krče (vključno z obračanjem zrkel), sindrom nemirnih nog, težave pri govoru, jecljanje, upočasnjen srčni utrip, občutljivost za sončno svetlobo, krvavitev iz nosa, trebušno distenzijo, izgubo spomina ali pozabljivost, urinsko inkontinenco, težave pri mokrenju, izgubo las, odsotnost ali zmanjšanje menstruacij ter spremembe na prsih pri moških in ženskah, kot na primer nenormalno nastajanje mleka v prsih ali nenormalna rast.
Changes in fasting glucose from borderline at baseline (≥5.56-<7 mmol/l) to high (≥7 mmol/l) were very common.
Zelo pogoste so bile spremembe v ravneh glukoze na tešče z mejnih osnovnih vrednosti (≥ 5,56 mmol/l - < 7 mmol/l) na visoke (≥ 7 mmol/l).
If you suddenly stop taking Olanzapine Teva, symptoms such as sweating, unable to sleep, tremor, anxiety or nausea and vomiting might occur.
Če nenadno prenehate jemati zdravilo Olanzapin Teva, se lahko pojavijo simptomi, kot so znojenje,
Thromboembolis m (including pulmonary embolism and deep vein thrombosis) (see section 4.4)
(vključno s pljučno embolijo in globoko vensko trombozo) (glejte poglavje 4.4)
Olanzapine Teva 7.5 mg film-coated tablets
Olanzapin Teva 7,5 mg filmsko obložene tablete
Excipient with known effect Each film-coated tablet contains 103.3 mg lactose.
Ena filmsko obložena tableta vsebuje 103,3 mg laktoze.
Excipient with known effect Each film-coated tablet contains 137.8 mg lactose.
Ena filmsko obložena tableta vsebuje 137,8 mg laktoze.
What you need to know before you take Olanzapine Teva
Kaj morate vedeti, preden boste vzeli zdravilo Olanzapin Teva Ne jemljite zdravila Olanzapin Teva
Following short term treatment (median duration 47 days), weight gain ≥7% of baseline body weight was very common (22.2%), ≥15% was common (4.2%) and ≥25% was uncommon (0.8%).
S kratkoročnim zdravljenjem (srednje trajanje 47 dni) povezano zvečanje telesne mase za ≥ 7 % od osnovne telesne mase je bilo zelo pogosto (22,2 %), ≥ 15 %
Olanzapine Teva 7.5 mg film-coated tablets Each film-coated tablet contains 7.5 mg olanzapine.
Olanzapin Teva 7,5 mg filmsko obložene tablete Ena filmsko obložena tableta vsebuje 7,5 mg olanzapina.
Each Olanzapine Teva 7.5 mg film-coated tablet contains 7.5 mg of the active substance.
Ena Olanzapin Teva 7,5 mg filmsko obložena tableta vsebuje 7,5 mg učinkovine.
Patients gaining ≥7%, ≥15% and ≥25% of their baseline body weight with long-term exposure (at least 48 weeks) were very common (64.4%, 31.7% and 12.3% respectively).
Zvečanje osnovne telesne mase za ≥ 7 % , ≥ 15 % in ≥ 25 % se je pri dolgoročni izpostavljenosti bolnikov (vsaj 48 tednov) pojavljalo zelo pogosto (v
Acute symptoms such as sweating, insomnia, tremor, anxiety, nausea, or vomiting have been reported rarely (≥0.01% and <0.1%) when olanzapine is stopped abruptly.
Redko (≥ 0,01 % in < 0,1 %) so pri nenadni prekinitvi zdravljenja z olanzapinom poročali o akutnih simptomih, kot so znojenje, nespečnost, tresenje, občutek tesnobe, slabost ali bruhanje.
Talk to your doctor or pharmacist before taking Olanzapine Teva.
Pred začetkom jemanja zdravila Olanzapin Teva se posvetujte z zdravnikom ali farmacevtom.
Each orodispersible tablet contains 95.0 mg lactose, 0.525 mg sucrose and 4.5 mg aspartame (E951).
Ena orodisperzibilna tableta vsebuje 95,0 mg laktoze, 0,525 mg saharoze in 4,5 mg aspartama (E951).
With long-term exposure (at least 24 weeks), 89.4% gained ≥7%, 55.3%gained ≥15% and 29.1% gained ≥25% of their baseline body weight.
pridobilo ≥ 7 %, 55,3 % ≥ 15 % in 29,1 % ≥ 25 % od njihove osnovne telesne mase.
15 Changes in total fasting cholesterol levels from normal at baseline (<4.39 mmol/l) to high
Zelo pogoste so bile spremembe v ravneh celokupnega holesterola na tešče z mejnih osnovnih vrednosti (≥ 4,39 mmol/l
Each Olanzapine Teva 20 mg orodispersible tablet contains 20 mg of the active substance.
Ena Olanzapin Teva 20 mg orodisperzibilna tableta vsebuje 20 mg učinkovine.
Olanzapine Teva 20 mg film-coated tablets Each film-coated tablet contains 20 mg olanzapine.
Olanzapin Teva 20 mg filmsko obložene tablete Ena filmsko obložena tableta vsebuje 20 mg olanzapina.
Olanzapine Teva contains lactose
Zdravilo Olanzapin Teva vsebuje laktozo
Olanzapine Teva 2.5 mg film-coated tablets Olanzapine Teva 5 mg film-coated tablets Olanzapine Teva 7.5 mg film-coated tablets Olanzapine Teva 10 mg film-coated tablets Olanzapine Teva 15 mg film-coated tablets Olanzapine Teva 20 mg film-coated tablets Olanzapine
Olanzapin Teva 2,5 mg filmsko obložene tablete Olanzapin Teva 5 mg filmsko obložene tablete Olanzapin Teva 7,5 mg filmsko obložene tablete Olanzapin Teva 10 mg filmsko obložene tablete Olanzapin Teva 15 mg filmsko obložene tablete Olanzapin Teva 20 mg filmsko obložene tablete olanzapin
28 orodispersible tablets 30 orodispersible tablets 35 orodispersible tablets 56 orodispersible tablets 70 orodispersible tablets 98 orodispersible tablets
28 orodisperzibilnih tablet 30 orodisperzibilnih tablet 35 orodisperzibilnih tablet 56 orodisperzibilnih tablet 70 orodisperzibilnih tablet 98 orodisperzibilnih tablet
People with this disease may also feel depressed, anxious or tense.
Ljudje s to boleznijo se lahko počutijo tudi depresivno, občutijo tesnobo ali napetost; - zmernih do resnejših maničnih epizod, bolezni s simptomi razburjenja ali eforije.
Excipient with known effect Each film-coated tablet contains 71.3 mg lactose.
Ena filmsko obložena tableta vsebuje 71,3 mg laktoze.
Olanzapine Teva 2.5 mg film-coated tablets Olanzapine Teva 5 mg film-coated tablets Olanzapine Teva 7.5 mg film-coated tablets Olanzapine Teva 10 mg film-coated tablets Olanzapine Teva 15 mg film-coated tablets Olanzapine Teva 20 mg film-coated tablets
Olanzapin Teva 2,5 mg filmsko obložene tablete Olanzapin Teva 5 mg filmsko obložene tablete Olanzapin Teva 7,5 mg filmsko obložene tablete Olanzapin Teva 10 mg filmsko obložene tablete Olanzapin Teva 15 mg filmsko obložene tablete Olanzapin Teva 20 mg filmsko obložene tablete
28 orodispersible tablets 30 orodispersible tablets 35 orodispersible tablets 50 orodispersible tablets 56 orodispersible tablets 70 orodispersible tablets 98 orodispersible tablets
28 orodisperzibilnih tablet 30 orodisperzibilnih tablet 35 orodisperzibilnih tablet 50 orodisperzibilnih tablet 56 orodisperzibilnih tablet 70 orodisperzibilnih tablet 98 orodisperzibilnih tablet
It may be harmful if you have phenylketonuria (PKU), a rare genetic disorder in which phenylalanine builds up because the body cannot remove it properly.
redko genetsko bolezen, pri kateri pride do kopičenja fenilalanina, ker se ne more ustrezno odstranjevati iz telesa.
Renal and urinary disorders
Urinska inkontinenca Zastajanje urina
Each Olanzapine Teva 20 mg film-coated tablet contains 20 mg of the active substance.
Ena Olanzapin Teva 20 mg filmsko obložena tableta vsebuje 20 mg učinkovine.
Olanzapine Teva 2.5 mg film-coated tablets Each film-coated tablet contains 2.5 mg olanzapine.
Olanzapin Teva 2,5 mg filmsko obložene tablete Ena filmsko obložena tableta vsebuje 2,5 mg olanzapina.
Colour mixture pink (polydextrose, hypromellose, glycerol triacetate, macrogol 8000, titanium dioxide E171, iron oxide red E172)
Olanzapin Teva 20 mg filmsko obložene tablete roza barvna mešanica (polidekstroza, hipromeloza, triacetin, makrogol 8000, titanov dioksid E171,
Each Olanzapine Teva 10 mg orodispersible tablet contains 10 mg of the active substance.
Ena Olanzapin Teva 10 mg orodisperzibilna tableta vsebuje 10 mg učinkovine.
What you need to know before you take Olanzapine Teva 3.
Kaj morate vedeti, preden boste vzeli zdravilo Olanzapin Teva Ne jemljite zdravila Olanzapin Teva:
- High blood sugar and high levels of fat (triglycerides and cholesterol) have been seen in patients taking Olanzapine Teva.
- Pri bolnikih, ki so jemali zdravilo Olanzapin Teva, so opazili visok nivo sladkorja v krvi in visok nivo maščob (trigliceridov in holesterola).
If you forget to take Olanzapine Teva Take your tablets as soon as you remember.
Vzemite tablete, kakor hitro se spomnite.
Each Olanzapine Teva 2.5 mg film-coated tablet contains 2.5 mg of the active substance.
- Ena Olanzapin Teva 2,5 mg filmsko obložena tableta vsebuje 2,5 mg učinkovine.
High Gamma
Trombembolija
Amenorrhea Breast enlargement Galactorrhea in females
galaktoreja pri ženskah, ginekomastija/
Risk factors that may predispose this patient population to increased mortality include age >65 years, dysphagia, sedation, malnutrition and dehydration, pulmonary conditions (e.g., pneumonia, with or without aspiration), or concomitant use of benzodiazepines.
obolenja pljuč (npr. pljučnica, z aspiracijo ali brez nje), ali sočasno uporabo benzodiazepinov.
Olanzapine Teva 20 mg film-coated tablets
Olanzapin Teva 20 mg filmsko obložene tablete
Olanzapine Teva 20 mg orodispersible tablets
Olanzapin Teva 20 mg orodisperzibilne tablete
Olanzapine Teva 20 mg orodispersible tablets are available in cartons containing 28, 30, 35, 56, 70 or 98 tablets.
Olanzapin Teva 20 mg orodisperzibilne tablete so na voljo v pakiranjih po 28, 30, 35, 56, 70 ali 98 tablet.
Each orodispersible tablet contains 20 mg olanzapine.
Ena orodisperzibilna tableta vsebuje: 20 mg olanzapina.
Each Olanzapine Teva 10 mg film-coated tablet contains 10 mg of the active substance.
Ena Olanzapin Teva 10 mg filmsko obložena tableta vsebuje 10 mg učinkovine.
Olanzapine Teva 15 mg film-coated tablets Each film-coated tablet contains 15 mg olanzapine.
Olanzapin Teva 15 mg filmsko obložene tablete Ena filmsko obložena tableta vsebuje 15 mg olanzapina.
Contents of the pack and other information
Shranjevanje zdravila Olanzapin Teva Vsebina pakiranja in dodatne informacije
Olanzapine Teva 5 mg orodispersible tablets A yellow, round, biconvex tablet, with 8 mm of diameter.
Olanzapin Teva 5 mg orodisperzibilne tablete Rumena, okrogla, bikonveksna tableta, premera 8 mm.
Olanzapine Teva 2.5 mg film-coated tablets EU/1/07/427/001 - 28 tablets, per box
Olanzapin Teva 2,5 mg filmsko obložene tablete EU/1/07/427/001 - 28 tablet v škatli
Olanzapine Teva 20 mg film-coated tablet is a pink, biconvex, oval film-coated tablet, debossed ”OL 20” on one side and plain on the other.
Olanzapin Teva 20 mg filmsko obložena tableta je roza, bikonveksna, ovalna filmsko obložena tableta z vtisnjenim napisom »OL 20« na eni strani in ravna na drugi strani.
Vascular disorders Orthostatic hypotension10
Ortostatska hipotenzija10
Olanzapine Teva 10 mg film-coated tablets Each film-coated tablet contains 10 mg olanzapine.
Olanzapin Teva 10 mg filmsko obložene tablete Ena filmsko obložena tableta vsebuje 10 mg olanzapina.
Hepatobiliary disorders Transient, asymptomatic elevations of hepatic aminotransferases (ALT, AST), especially in early treatment (see section 4.4)
Prehodna asimptomatska zvišanja jetrnih aminotransferaz (ALT, AST),
Each Olanzapine Teva 5 mg orodispersible tablet contains 5 mg of the active substance.
Ena Olanzapin Teva 5 mg orodisperzibilna tableta vsebuje 5 mg učinkovine.
Olanzapine Teva belongs to a group of medicines called antipsychotics and is used to treat the following conditions: - Schizophrenia, a disease with symptoms such as hearing, seeing or sensing things which are not there, mistaken beliefs, unusual suspiciousness, and becoming withdrawn.
- shizofrenije, bolezni s simptomi, kot so prisluhi, prividi ali občutki, ki niso povezani z realnostjo, zmotna prepričanja, nenavadna sumničavost in postopno izogibanje socialnim stikom.
Each Olanzapine Teva 15 mg orodispersible tablet contains 15 mg of the active substance.
Ena Olanzapin Teva 15 mg orodisperzibilna tableta vsebuje 15 mg učinkovine.
muscle stiffness and drowsiness or sleepiness.
nespečnost, tresenje, občutek tesnobe ali slabost in bruhanje.
Olanzapine Teva 15 mg orodispersible tablets
Olanzapin Teva 15 mg orodisperzibilne tablete
Olanzapine Teva 5 mg film-coated tablets Each film-coated tablet contains 5 mg olanzapine.
Olanzapin Teva 5 mg filmsko obložene tablete Ena filmsko obložena tableta vsebuje 5 mg olanzapina.
Tablet coating: hypromellose, polydextrose, glycerol triacetate, macrogol 8000, titanium dioxide (E171).
Jedro tablete: laktoza monohidrat, hidroksipropilceluloza, krospovidon (vrsta A), brezvodni koloidni silicijev dioksid, mikrokristalna celuloza, magnezijev stearat, Ovoj tablete: hipromeloza, polidekstroza, triacetin, makrogol 8000, titanov dioksid (E171).
Olanzapine Teva 7.5 mg film-coated tablet is a white, biconvex, round film-coated tablet, debossed ”OL 7.5” on one side and plain on the other.
Olanzapin Teva 7,5 mg filmsko obložena tableta je bela, bikonveksna, okrogla filmsko obložena tableta z vtisnjenim napisom »OL 7,5« na eni strani in ravna na drugi strani.
Olanzapine Teva 15 mg film-coated tablets
Olanzapin Teva 15 mg filmsko obložene tablete
Olanzapine Teva 15 mg film-coated tablets are available in cartons of 28, 30, 35, 50, 56, 70 or 98 filmcoated tablets.
Olanzapin Teva 15 mg filmsko obložene tablete so na voljo v pakiranjih po 28, 30, 35, 50, 56, 70 ali 98 filmsko obloženih tablet.
Olanzapine Teva 5 mg orodispersible tablets
Olanzapin Teva 5 mg orodisperzibilne tablete
Restless legs syndrome
Nevroleptični maligni sindrom
Olanzapine Teva 15 mg film-coated tablets EU/1/07/427/016 - 28 tablets, per box
Olanzapin Teva 15 mg filmsko obložene tablete EU/1/07/427/016 - 28 tablet v škatli
Olanzapine Teva 7.5 mg film-coated tablets EU/1/07/427/008 - 28 tablets, per box EU/1/07/427/077 - 28 x 1 tablets, per box EU/1/07/427/009 - 30 tablets, per box EU/1/07/427/078 - 30 x 1 tablets, per box EU/1/07/427/040 - 35 tablets, per box EU/1/07/427/079 - 35 x 1 tablets, per box EU/1/07/427/010 - 56 tablets, per box EU/1/07/427/080 - 56 x 1 tablets, per box EU/1/07/427/068 - 60 tablets, per box EU/1/07/427/050 - 70 tablets, per box EU/1/07/427/081 - 70 x 1 tablets, per box EU/1/07/427/060 - 98 tablets, per box EU/1/07/427/082 - 98 x 1 tablets, per box
Olanzapin Teva 7,5 mg filmsko obložene tablete EU/1/07/427/008 - 28 tablet v škatli EU/1/07/427/077 - 28 x 1 tableta v škatli EU/1/07/427/009 - 30 tablet v škatli EU/1/07/427/078 - 30 x 1 tableta v škatli EU/1/07/427/040 - 35 tablet v škatli EU/1/07/427/079 - 35 x 1 tableta v škatli EU/1/07/427/010 - 56 tablet v škatli EU/1/07/427/080 - 56 x 1 tableta v škatli EU/1/07/427/068 - 60 tablet v škatli EU/1/07/427/050 - 70 tablet v škatli EU/1/07/427/081 - 70 x 1 tableta v škatli EU/1/07/427/060 - 98 tablet v škatli EU/1/07/427/082 - 98 x 1 tableta v škatli
Olanzapine Teva 10 mg orodispersible tablets
Olanzapin Teva 10 mg orodisperzibilne tablete
28 film-coated tablets 30 film-coated tablets 35 film-coated tablets 56 film-coated tablets 70 film-coated tablets 98 film-coated tablets
28 filmsko obloženih tablet 30 filmsko obloženih tablet 35 filmsko obloženih tablet 56 filmsko obloženih tablet 70 filmsko obloženih tablet 98 filmsko obloženih tablet
Olanzapine Teva 20 mg film-coated tablets EU/1/07/427/020 - 28 tablets, per box
Olanzapin Teva 20 mg filmsko obložene tablete EU/1/07/427/020 - 28 tablet v škatli
Each orodispersible tablet contains 5 mg olanzapine.
Ena orodisperzibilna tableta vsebuje: 5 mg olanzapina.
Olanzapine Teva 20 mg orodispersible tablets EU/1/07/427/035 - 28 tablets, per box
Olanzapin Teva 20 mg orodisperzibilne tablete EU/1/07/427/035 - 28 tablet v škatli
Very common symptoms in overdose (>10% incidence) include tachycardia, agitation/aggressiveness, dysarthria, various extrapyramidal symptoms, and reduced level of consciousness ranging from sedation to coma.
vznemirjenost/nasilnost, dizartrijo, različne ekstrapiramidne simptome in motnje zavesti v razponu od sedacije do kome.